Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 3/20 | 0.43 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 15/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 11/20 | 0.41 |
| ▸ | AHCY | P23526 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | NNMT | P40261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25048785 | 1.00 | METTL3 (0.43) | METTL3METTL14PRMT5WDR77AHCY | |
| SCHEMBL31617943 | 0.88 | PRMT5 (0.47) | METTL3METTL14PRMT5WDR77AHCY | |
| SCHEMBL25048839 | 0.88 | PRMT5 (0.53) | METTL3METTL14PRMT5WDR77 | |
| SCHEMBL25049339 | 0.85 | PRMT5 (0.41) | METTL3METTL14PRMT5WDR77AHCY | |
| SCHEMBL25047871 | 0.84 | METTL3 (0.57) | METTL3METTL14PRMT5WDR77AHCY | |
| SCHEMBL31617857 | 0.84 | METTL3 (0.57) | METTL3METTL14PRMT5WDR77AHCY | |
| SCHEMBL25049345 | 0.84 | CHKA (0.41) | METTL3METTL14PRMT5WDR77AHCY | |
| SCHEMBL25048467 | 0.84 | PRMT5 (0.39) | METTL3METTL14PRMT5WDR77AHCY | |
| SCHEMBL25048835 | 0.83 | PRMT5 (0.41) | METTL3METTL14PRMT5WDR77AHCY | |
| SCHEMBL25048466 | 0.83 | PRMT5 (0.39) | METTL3METTL14PRMT5WDR77AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | METTL3 166/4885METTL14 883/4885PRMT5 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.